Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 in Advanced TCC
NCT01856101Phase 2
Key facts
- Status
- Terminated
- Start
- Feb 2013
- Primary completion
- Jan 2014
- Countries
- 2
- Modality
- Small Molecules
- Drugs
- dactolisib
- Conditions
- transitional cell carcinoma (TCC)
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in transitional cell carcinoma (TCC). Primary endpoint: Disease Control Rate at 16 weeks. Started Feb 2013; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
BEZ235
Patients receive BEZ235 (dactolisib) monotherapy.
03
Who it enrols
Patients with locally advanced or metastatic TCC who have progressed after first-line platinum-based therapy, with adequate organ function and no prior PI3K/mTOR inhibitor treatment.
04
Endpoints
Primary
Disease Control Rate
Secondary
Safety Profile
Beyond the preview
Go deeper on NCT01856101.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856101.